GlucoTrack news

Glucotrack is gaining access to a Nasdaq listing through the combination and will continue operating its CBGM business as a subsidiary of the combined entity, providing stability and growth opportunities through the merger with Lōkahi Therapeutics.

The completion of the strategic business combination provides Glucotrack with public market access, capital-efficient operations, and integration with Lōkahi's ai²-driven platform. The company gains access to a broader asset sourcing and development framework while maintaining its CBGM technology as a focused subsidiary, positioning it for scalable growth and strategic opportunities.

Company achieved significant regulatory milestone with FDA IDE submission, demonstrated scientific validation through peer-reviewed publications showing 6.8% MARD accuracy over 240 days, reduced net losses year-over-year, decreased debt obligations, and is on track for clinical trial initiation in H2 2026. However, positive sentiment is tempered by declining cash position ($3.9M from $7.4M) and limited runway into early Q3 2026, creating near-term funding pressure.

The company achieved a significant regulatory milestone by submitting its IDE application to the FDA, which is a critical step toward clinical evaluation and commercialization. The announcement demonstrates substantial progress in preclinical development and positions the company closer to bringing an innovative implantable glucose monitoring solution to market. The technology offers meaningful advantages over existing wearable solutions, supporting positive investor sentiment.

Company demonstrated operational progress with improved net loss ($19.4M vs $22.6M), strengthened IP portfolio with three new patents, secured $4.0M in funding, and is advancing toward key regulatory milestones (IDE submission Q2 2026, clinical trials H2 2026). Cash position improved and company states existing cash is sufficient to fund 2026 operations through IDE submission and trial initiation.